Xeris Biopharma Holdings, Inc. Common Stock (XERS) Stock Price, Quote & AI Analysis

Live XERS stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Xeris Biopharma Holdings, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Xeris Biopharma Holdings, Inc. Common Stock (XERS), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

X
XERS
Xeris Biopharma Holdings, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
0.000000
High
0.000000
Low
0.000000
Volume
0
VWAP
-
Market Cap
$1,221,202,767.04
52W Range
$3.45 - $10.08
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 4, 2026 Q4
After Hours
EPS Estimate: $0.0449
Revenue Estimate: $83,986,800.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Xeris Biopharma Holdings, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Xeris Biopharma Holdings, Inc. Common Stock Overview

Company information

Company Overview

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Company Details
Market Cap
$1.22B
Shares Outstanding
165,924,275
Weighted Shares Outstanding
165,924,289
CEO
John Patrick Shannon
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607
Employees
394
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Xeris Biopharma Holdings, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...